CD9 Counteracts Liver Steatosis and Mediates GCGR Agonist Hepatic Effects

Advanced Science, Journal Year: 2024, Volume and Issue: 11(29)

Published: June 5, 2024

Abstract Glucagon receptor (GCGR) agonism offers potentially greater effects on the mitigation of hepatic steatosis. However, its underlying mechanism is not fully understood. Here, it screened tetraspanin CD9 might medicate GCGR agonist. decreased in fatty livers patients and upregulated upon activation. Deficiency liver exacerbated diet‐induced steatosis via complement factor D (CFD) regulated acid metabolism. Specifically, modulated synthesis oxidation genes through regulating CFD expression ubiquitination‐proteasomal degradation FLI1. In addition, influenced body weight by modulating lipogenesis thermogenesis adipose tissue CFD. Moreover, reinforcement alleviated steatosis, blockage abolished remission induced cotadutide treatment. Thus, medicates beneficial signaling, may server as a promising therapeutic target for

Language: Английский

Fructose Metabolism in Entner-Doudoroff Pathway-deficient Cupriavidus necator H16 Depends on the Calvin Shunt

Microbiological Research, Journal Year: 2025, Volume and Issue: 298, P. 128222 - 128222

Published: May 14, 2025

Language: Английский

Phospholipase D2 drives cellular lipotoxicity and tissue inflammation in alcohol-associated liver disease

Life Sciences, Journal Year: 2024, Volume and Issue: 358, P. 123166 - 123166

Published: Oct. 22, 2024

Language: Английский